Short Interest in BioVie Inc. (NASDAQ:BIVI) Expands By 36.3%

BioVie Inc. (NASDAQ:BIVI) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, an increase of 36.3% from the November 15th total of 1,350,000 shares. Based on an average daily volume of 5,810,000 shares, the short-interest ratio is presently 0.3 days.

BioVie Trading Up 1.9 %

BioVie stock traded up $0.05 during mid-day trading on Friday, reaching $2.64. The company had a trading volume of 1,861,319 shares, compared to its average volume of 1,685,683. The business has a fifty day simple moving average of $2.57 and a 200 day simple moving average of $1.81. The company has a market cap of $46.91 million, a P/E ratio of -0.23 and a beta of 0.40. BioVie has a fifty-two week low of $1.04 and a fifty-two week high of $33.10.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings data on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.